BIOMAT Database Logo BIOMAT Database Logo

A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. 1992

J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064.

A-77636, ((1R,3S) 3-(1'-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benz opyran hydrochloride), is a selective dopamine D1 receptor agonist. In a battery of receptor binding assays, A-77636 shows the highest affinity (pKi = 7.40 +/- 0.09; Ki = 39.8 nM) for the dopamine D1 receptor. A-77636 is an agonist at the dopamine D1 receptors in the fish retina (pEC50 = 8.13; EC50 = 1.1 nM; intrinsic activity = 102% of dopamine) and the rat caudate-putamen (pEC50 = 8.97; intrinsic activity = 134% of dopamine). The compound is functionally inactive at dopamine D2 receptors (EC50 > 10 microM). In rats with unilateral 6-OHDA (6-hydroxydopamine) lesions of the nigro-striatal dopaminergic pathway, A-77636 elicits prolonged (> 20 h) contralateral turning that is blocked by SCH 23390, a D1 receptor antagonist, but not by haloperidol at doses selective for the dopamine D2 receptor. Higher doses of A-77636 produce forelimb clonus in rats and mice. When tested in marmosets treated with MPTP to induce a parkinsonian-like state, A-77636 increases locomotor activity and decreases the severity of the parkinsonian-like symptoms: the compound is active after either subcutaneous or oral administration. A-77641, the optical antipode of A-77636, has a lower affinity towards the dopamine D1 receptor (pKi = 5.14, Ki = 7200 nM), is less potent as a dopamine D1 receptor agonist (pEC50 = 5.65; EC50 = 2200 nM), fails to elicit turning in the 6-OHDA-lesioned rat, and lacks antiparkinsonian efficacy in the MPTP-treated marmoset.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D002144 Callithrix A genus of the subfamily CALLITRICHINAE occurring in forests of Brazil and Bolivia and containing seventeen species. Callithrix jacchus,Hapale,Marmoset, Common,Marmoset, Short-Tusked,Marmosets,Common Marmoset,Common Marmosets,Marmoset,Marmoset, Short Tusked,Short-Tusked Marmoset,Short-Tusked Marmosets
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005399 Fishes A group of cold-blooded, aquatic vertebrates having gills, fins, a cartilaginous or bony endoskeleton, and elongated bodies covered with scales.
D000218 Adamantane A tricyclo bridged hydrocarbon. Diamantane
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
The potent and selective dopamine D1 receptor agonist A-77636 increases cortical and hippocampal acetylcholine release in the rat.
July 1994, European journal of pharmacology,
J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity.
September 2019, ACS chemical neuroscience,
J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
Addition to "Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity".
April 2021, ACS chemical neuroscience,
J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
A68930: a potent agonist selective for the dopamine D1 receptor.
June 1991, European journal of pharmacology,
J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist.
April 1993, European journal of pharmacology,
J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
The anorectic effect of the selective dopamine D1-receptor agonist A-77636 determined by meal pattern analysis in free-feeding rats.
February 2006, European journal of pharmacology,
J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
January 1989, Movement disorders : official journal of the Movement Disorder Society,
J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636.
March 1996, The Journal of pharmacology and experimental therapeutics,
J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
January 2020, Journal of Parkinson's disease,
J W Kebabian, and D R Britton, and M P DeNinno, and R Perner, and L Smith, and P Jenner, and R Schoenleber, and M Williams
A D1/D2 chimeric dopamine receptor mediates a D1 response to a D2-selective agonist.
May 1993, FEBS letters,
Copied contents to your clipboard!